Roche touts PhII win for BTK in­hibitor in mul­ti­ple scle­ro­sis as PhI­II show­down with Sanofi, Mer­ck KGaA, No­var­tis looms

Roche is stak­ing its claim in the race to de­vel­op a BTK in­hibitor for mul­ti­ple scle­ro­sis, with a topline Phase II win show­ing its can­di­date re­duced brain le­sions.

There are no num­bers yet — Roche and its sub­sidiary Genen­tech are sav­ing those for a med­ical meet­ing — but the com­pa­nies sug­gest­ed that the pos­i­tive re­sult bodes well for the Phase III tri­als they are run­ning for in re­laps­ing MS and pri­ma­ry pro­gres­sive MS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.